It is now the 3rd CHALLENGE Period for CACAO Fall 2017! It will end on Sunday October 22, 2017 at 11:59 pm CDT
This is your chance to challenge other team's annotations. You may also DEFEND or suggest improvements to your own annotations IF they have been challenged. Please note, although we ENCOURAGE challenges, an excess of identical challenges that do not appear to be applicable to the annotation or well thought out will be considered spam and ignored.

Have any questions? Please email us at


Jump to: navigation, search

Two izoenzymes of cyclooxygenase, COX-1 and COX-2, are proven to catalyze the rate-limiting step in prostaglandin synthesis. This enzyme is the target of nonsteroidal anti-inflammatory drugs, mainly Acetaminophen.

Cyclooxygenase-2, COX-2, is overexpressed in colon cancer, suggesting a relationship between the pathway and signaling of COX-2 and colorectal carcinogens. When COX-2 activity is inhibited by sulindac, a metabolite of sulindac sulfoxide, the average diameter and number of polyps decreased in patients affected by colorectal cancers.

See also

The role of cyclooxygenase-2 in Colon Cancer. [1]

COX-3: Cloning, Structure, and Expression [2]

Variants of cyclooxygenase-1 and their roles in medicine. [3]


See Help:References for how to manage references in GONUTS.

  1. Eisinger, AL et al. (2007) The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat. 82 147-54 PubMed GONUTS page
  2. Chandrasekharan, NV et al. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U.S.A. 99 13926-31 PubMed GONUTS page
  3. Simmons, DL (2003) Variants of cyclooxygenase-1 and their roles in medicine. Thromb. Res. 110 265-8 PubMed GONUTS page

External links